chrisvoncsefalvay/vaers-outcomes huggingface dataset:
New symptomatic Anemia  -Required 2 units of packed RBC's transfusion on admission. He wants to go home, and return for follow up, stable labs, and stable exam, d/w oncology team today, he cleared him to dc today, with close outpatient follow up to guide further care. ED visit to hospital admission within 6 weeks of receiving the COVID vaccine.
Client fainted, leaned to left, clenched fists and yees rooled back- lasted aprox 5 sec- disorientated for 10-15 seconds, then nauseated, pale and diaphoretic.  Remained in office for 20 minutes.  Denied needing care when leaving except said she felt fatigued.
Information has been received from a registered nurse regarding a patient of an unknown age and gender. On 03-MAR-2012 at 11:30 ZOSTAVAX (Lot # 672476/1605AA) was exposed to -12 degrees C for an estimated total time out of range of 4 hours. On 16-MAR-2012, the patient was vaccinated with an out of range dose of ZOSTAVAX (Lot # 672476/1605AA, expiration date of 13-JAN-2013) (dose and route of administration were not provided). No adverse experience was reported. This is one of 182 reports from the same source. Additional information has been requested.
Patient reported having the following symptoms: body aches, nausea, severe chills, then fever.  The symptoms began at midnight and appeared to resolve at 3:30 AM.  Upon awakening this morning, he reported that felt a little sore and a little weak.
Progressively thru the night patient was feeling more achy all over body, no appetite/nausea, headache, runny nose (slight) backache. Patient was not sleeping well at 3 AM and got up to take Tylenol. Patient was so weak. Patient fell over and fainted. Had severe sweating then chills thru the night.
Pain in left arm started four hours after injection could not life or move arm without pain. 24 hours after injection had elevated temp of 100.5 and red blotches below the injection site (but not at the injection site). 72 hours after injection temperature returned to normal and pain was slowly diminishing. 96 hours after injection pain is gone, red blotches are fading. 10 days after injection, red blotches are gone.
rash on upper and lower extremities, chest and shoulder Prednison taper given to pt
Acute Reaction: Burning pain upon injection, feeling like they're going to faint.  Chronic Reaction over the course of the last two weeks: Burning pain, radiating down the arm and up to neck; Numbness down left arm, up to eye and into spine.   Treatment with Ibuprofen thus far unsuccessful.
Pt. received H1N1 vaccine at 13:30 and started feeling dizzy and short of breath by 14:00. She reported to this office and was observed, with discharge at 15:15.
had the second dose of the Pfizer Covid-19 vaccine and felt like she had Covid-19 afterwards; had the second dose of the Pfizer Covid-19 vaccine and felt like she had Covid-19 afterwards; This is a spontaneous report from a contactable consumer or other non-HCP (reporter who was also a patient reported for her Niece). A 66-year-old female patient received second dose of BNT162B2 (COMIRNATY, Solution for injection, Lot number was not reported), via an unspecified route of administration on an unspecified date as DOSE 2, SINGLE (Age of vaccination: Unknown) for COVID-19 immunization. Medical history and concomitant mediocations were not reported. Her (patient's) whole family had COVID-19. Patient had earlier received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot number was not reported), via an unspecified route of administration on an unspecified date as dose 1, single (Age of vaccination: Unknown) for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. On an unspecified date the patient received the second dose of the Pfizer covid-19 vaccine and felt like she had covid-19 afterwards. Therapeutic measures were taken as a result of the events, took Tylenol. The outcome of the events was unknown.
Patient reports swollen injection site, reddish in color, then whelps all around at back of neck, arms and chest since yesterday but seems to be diminishing today.
Patient was almost died from  the hospital; Initial information received on 13-Oct-2021 regarding an unsolicited valid serious case received from a consumer or non-health care professional via social media.  This case involves adult patient who experienced had almost died from the hospital (unevaluable event) had always go, because had doctor begged her after receiving INFLUENZA VACCINE.  It was unknown if the patient had any medical history, concomitant disease or risk factor.  The patient past medical treatment, vaccination, family history and concomitant medication were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE. [lot number and expiry date not reported] via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date the patient developed a serious almost died from the hospital (unevaluable event) (unknown latency) following the administration of INFLUENZA VACCINE.  Near death experience event was assessed as medically significant.  It was unknown if there were lab data/results available.  It was unknown if the patient experienced any additional symptoms/events.  It was not reported if the patient received a corrective treatment for the event.  At time of reporting, the outcome was unknown for the event.  There will be no information available on the batch number for this case.; Sender's Comments: This case involves adult patient who experienced unevaluable event after the vaccination with INFLUENZA VACCINE (unknown manufacturer).Time of onset is unknown. Further information regarding medical condition during vaccination, previous vaccination and tolerance, other laboratory investigations excluding alternative etiologies for the reported event are needed to fully assess this case. Based upon the reported information, the role of the suspect vaccine cannot be assessed.
Peripheral Neuropathy flared up after Covid19  2nd shot.  As soon as I received 2nd shot (Feb 25), I felt sensations in feet (heavy, like feet "asleep'").  Over 1st week had sensations in feet, lower legs - tingling, needles & pins, burning sensation, and feet feel like "asleep". Over time got worse, with tingling, burning, needles and pins in places, I never had before -- upper legs, thighs, arms and face.  This is more than my original Neuropathy.  Has taken awhile to get appt. with Neurology doctor.  Last few weeks, seems to be getting a little better.  Don't feel in arms as much, but feel more in face.
Sore Throat; Earache; This spontaneous case was reported by a consumer and describes the occurrence of OROPHARYNGEAL PAIN (Sore Throat) and EAR PAIN (Earache) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Feb-2021, the patient experienced OROPHARYNGEAL PAIN (Sore Throat) and EAR PAIN (Earache). At the time of the report, OROPHARYNGEAL PAIN (Sore Throat) and EAR PAIN (Earache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication were not reported  Treatment medication information were not reported   Most recent FOLLOW-UP information incorporated above includes: On 26-Apr-2021: Follow Up received on 26-Apr-2021 contains non significant information
she was given the second dose of the Pfizer Covid vaccine subcutaneously rather than IM; redness to her arm around the injection site; This is a spontaneous report received from a contactable consumer (patient) from a Pfizer sponsored program via medical information team. A female patient of unspecified age received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, lot number was not reported), subcutaneously on 27May2021 as single dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, lot number was not reported), dose 1 on unspecified date for covid-19 immunisation. The patient stated that she was given the second dose of the Pfizer Covid vaccine subcutaneously rather than IM (intramuscular). She stated that she had the second dose of the Pfizer Covid vaccine on the 27May2021. She noticed redness to her arm around the injection site but not on it which was resolving. The patient queried that "Can I go get a Antibody test to determine if I am protected" and the response was as follows: CDC states that antibody testing is not recommended to assess for immunity to SARS-CoV-2 [the virus that causes COVID-19] following COVID-19. In addition, antibody tests currently authorized under an Emergency Use Authorization (EUA) are not authorized for the review of an immune response in vaccinated people. The patient also queried that "If I was given the vaccine subcutaneously rather than in the muscle, I'm I protected fully? I spoke to the pharmacist where I had the vaccine and they said it would be alright. Outcome of the event redness to her arm around the injection site was reported as resolving.  Information about lot/batch number is requested.
Normal headaches a day or so after the shot . 7 days after vaccination I had a severe migraine with loss of speech and loss of controlling left arm.  I was taken to the ER. EMTs concerned about stroke. Given meds, hydration in ER. Scans and tests, symptoms gone after a few hours. Kept for observation and follow up tests overnight, discharged next morning. No significant symptoms.
PATIENT HAD A LARGE LOCAL REACTION 10CM IN DIAMETER. WARM TO TOUCH ON RIGHT DELTOID. PATIENT ADVISED TO ICE THE SITE, KEEP A COURSE OF TYLENOL TO TRY TO MITIGATE PAIN AND SWELLING FROM THE INJECTION SITE, AND TO APPLY ICE. PATIENT ALSO ADVISED INFORM US AGAIN IF SYMPTOMS GET WORSE OR FAIL TO IMPROVE. PATIENT VERBALIZED UNDERSTANDING.
tired; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 71 year-old male patient received bnt162b2 (BNT162B2), administered in arm right, administration date 27Feb2021 (Lot number: EN6203) at the age of 70 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Glaucoma" (unspecified if ongoing), notes: Verbatim: Glaucoma, takes 2 eye drops for Glaucoma but does not know the names; "bee allergies" (unspecified if ongoing), notes: caller has a bee allergies and was desensitized years ago. Concomitant medication(s) included: ATORVASTATIN. Vaccination history included: Bnt162b2 (Dose:01, Anatomical location: right arm, lot number: EL9264), administration date: 06Feb2021, when the patient was 70 years old, for COVID-19 immunization. The following information was reported: FATIGUE (non-serious) with onset 27Feb2021, outcome "recovered" (2021), described as "tired".  Additional information: No additional vaccines administered on same date of the Pfizer Suspect. AE(s) did not require a visit to emergency room and physician office. No prior vaccinations within 4 weeks. AE(s) not following prior vaccinations. No relevant tests. It was reported that, patient was just tired after the first two shots. The caller clarifies and confirms that he was only tired after the second and third dose. After the second dose the caller was tired on 27Feb2021 but he recovered completely before receiving the third dose.   Follow-up attempts are completed. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202101410976 Same patient, same drug with different dose, different AE
The caller states she is almost well except she does still have a little pain in her arm where she received the injection.; Hard (at injection site); Itchy (at injection site); Real, Real Red (at injection site); Hot (at injection site); This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Hot (at injection site)), VACCINATION SITE PAIN (The caller states she is almost well except she does still have a little pain in her arm where she received the injection.), VACCINATION SITE INDURATION (Hard (at injection site)), VACCINATION SITE PRURITUS (Itchy (at injection site)) and VACCINATION SITE ERYTHEMA (Real, Real Red (at injection site)) in an 85-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure and Cholesterol. Concomitant products included PROBIOTICS NOS for an unknown indication.    On 25-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Aug-2021, the patient experienced VACCINATION SITE WARMTH (Hot (at injection site)), VACCINATION SITE INDURATION (Hard (at injection site)), VACCINATION SITE PRURITUS (Itchy (at injection site)) and VACCINATION SITE ERYTHEMA (Real, Real Red (at injection site)). On an unknown date, the patient experienced VACCINATION SITE PAIN (The caller states she is almost well except she does still have a little pain in her arm where she received the injection.). The patient was treated with CALAMINE for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE WARMTH (Hot (at injection site)), VACCINATION SITE INDURATION (Hard (at injection site)), VACCINATION SITE PRURITUS (Itchy (at injection site)) and VACCINATION SITE ERYTHEMA (Real, Real Red (at injection site)) was resolving and VACCINATION SITE PAIN (The caller states she is almost well except she does still have a little pain in her arm where she received the injection.) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication included pills for blood pressure and cholesterol. Treatment also included  ice bags which have helped to take away the redness and an ointment that isn't Benadryl, but similar. Patient  is scheduled to receive the second dose on 28AUG2021.   Patient went to the pharmacy and the pharmacist said she may have cellulitis. Then she  went to the doctor and did not have cellulitis because she didn't have a fever. The caller's physician has told her not to receive the second dose.
Patient received a booster dose of Pfizer COVID vaccine on 12/8/21. The next day, she said she started with a large bruise on her left upper arm.  The bruise on exam did not blanch and covered the anterior part of her left upper arm. She also developed bilateral lower leg swelling, and exam showed pitting 3+ edema. Labs and ECG were grossly normal. Spoke to her today, and she said the large bruise is slowly fading. Edema is slowly resolving with furosemide 20mg.
This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (601 doses were given after expiration date) and PRODUCT STORAGE ERROR (601 doses were given after expiration date) in an 18-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008C21A) for COVID-19 vaccination. No Medical History information was reported. On 29-Oct-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (601 doses were given after expiration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (601 doses were given after expiration date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (601 doses were given after expiration date) and PRODUCT STORAGE ERROR (601 doses were given after expiration date) outcome was unknown. Not Provided. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. No concomitant medications were reported. No treatment medications were reported. The vaccine was placed in refrigerator on 26 Sep 2021. There was no temperature excursion. No adverse event was reported.
Left arm muscle tightness, at site of injection, some nerve pain. Discomfort lasted about 2 months.
arm is a little sore; Initial information received on 09-Dec-2022 regarding an unsolicited valid Social media non-serious case from a consumer/non-health care professional.  This case involves Adult and unknown gender patient whose arm is a little sore after receiving vaccine Influenza Vaccine.  It is unknown if the patient had any medical history, concomitant disease or risk factor. The patient's past medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect influenza vaccine produced by unknown manufacturer (strength, frequency, formulation, dose, lot number, expiry date: not reported) via unknown route in unknown administration site for prophylactic vaccination (Immunisation).  On an unknown date the patient's arm is a little sore (pain in extremity) (unknown latency) following the administration of influenza vaccine.  It was reported "as Just got his Wednesday. his arm was a little sore and that's it. He had a business to run and can't afford to get sick".  No lab data was reported.  Action taken was not applicable.  It was not reported if the patient received a corrective treatment for the event.   The outcome was Unknown.
Tennis ball size erythema with 1/4 inch swelling from background skin. Went to urgent care.
Information has been received from a medical assistant concerning a 77 year old male, with no known allergies and no medical history reported, who on approximately 18-MAY-2008 was vaccinated with ZOSTAVAX (Oka/Merck). There was no concomitant medication. The patient experienced intermittent fever after receiving ZOSTAVAX (Oka/Merck). He was given a prescription for ZOSTAVAX (Oka/Merck) on 12-MAY-2008 to be filled and given at another facility. He was seen on 21-MAY-2008 in the physician office because of the fever. There were no laboratory diagnostic studies performed. At the time of reporting, the outcome of the patient was unknown. There was no product quality complaint. Additional information has been requested.
Itchiness and hotness, still itches today after 2 wks, pt using hydrocortisone cream. She said it also caused numbness travelling from upper arm to forefinger but that has resolved.
Pt recv vax on unknown dy; on same dy pt exp angioedema w/ red/blotchy area on hands & LL
Myalgias, joint pain in all large joints (knees, elbows and shoulders).
COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 30-year-old male patient received BNT162b2 (BNT162B2), on 10Nov2021 as dose 3 (booster), single at the age of 29 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant), outcome "not recovered" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Rebound, notes: COVID-19 rebound after completing treatment. Therapeutic measures were taken as a result of covid-19, drug ineffective.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
This is a spontaneous report from a contactable pharmacist. A patient of unspecified age ethnicity and gender started to receive PREVENAR 13, via an unspecified route of administration from an unspecified date to an unspecified date at 1 DF. The patient medical history was not reported. The patient's concomitant medications were not reported. The patient experienced rash at injection site on an unspecified date with outcome of unknown. The action taken in response to the event for PREVENAR 13 was not applicable. Follow-up (19Dec2014): Follow-up attempts completed. No further information expected.
No additional AE; Nurse reported VARIVAX  was administered after TE; see TE case 02487539. See full details below. No additional AE/no PQCs.    ?    Names of vaccines involved VARIVAX X000532 1/4/2025        ?    Temperature 8.1°F        ?    Time frame 3 hours; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. No information on patient's medical history, current conditions and concomitant medications was provided.  On 21-SEP-2023 the patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) lot # X000532 and expiration date 04-JAN-2025, for prophylaxis (exact dose, dose number, route and site of administration were not provided) (product storage error and no adverse event). The temperature excursion lasted for 3 hours 0 minutes 0 seconds in 8.1 Fahrenheit degrees (F).
Received First Dose Heplisav-B, 2nd Dose Engerix-B; Initial Report Received on 28-Jun-2023   A medical assistant reported that a 58-year-old female (race and ethnicity not provided), received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization as the first dose and Engerix-B as the second dose.    No medical history, allergies, or concomitant medications at the time of vaccination were reported.    On 17-May-2023, the patient received the first dose of HEPLISAV-B (Lot # 938794, expiration date 09-Aug-2023, and NDC # not reported) intramuscularly in the left deltoid.    On 14-Jun-2023, 29 days after having been vaccinated with HEPLISAV-B, the patient received Engerix-B as the second dose (Lot #, expiration date, and NDC # not reported). No concomitant medications were given. There were no adverse reactions witnessed with the patient.    No additional information was reported.    Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.
Pt states she had low BP, low pulse O2, fatigue and dizziness for aprox 24 hrs post 2nd shingrix shot
sick; Initial information was received on 21-Nov-2020 regarding an unsolicited valid non-serious case from a consumer (patient) via social media along with the live follow up received on 02-Dec-2020 processed together.  This case involves a patient (unknown demographics) who was sick (illness), while received INFLUENZA VACCINE.  Medical history, past medical treatment, vaccination, family history and concomitant medications were not provided.  On an unknown date, the patient received an INFLUENZA VACCINE (one dose) (Produced by unknown manufacturer) [lot number, expiry date and other dosing details were not reported] for prophylactic vaccination.  On an unknown date, patient was sick (illness) (unknown latency), following the administration of INFLUENZA VACCINE. It was reported that the patient never had another (second) one. It was reported that the vaccine could caused flu as well.  Details of laboratory data not reported.  Corrective treatment and outcome were unknown at the time of reporting.  There will be no information available on the batch number for this case.
Swelling at injection site. Next day, headache, mild sore throat fatigue x 2 days. Dx allergic reaction. Rx Prednisone 30mg x 3 days.